The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Bristol-Myers Squibb's 2013 sales performance.
Bristol Myers Squibb (BMS) and the Janssen Pharmaceutical Companies of Johnson &Johnson have announced that all three prospective antithrombotic indications for milvexian have been granted fast track designation by the US
Bristol Myers Squibb (BMS) has announced positive results from a phase 2 study evaluating its investigational antifibrotic treatment in patients with idiopathic pulmonary fibrosis (IPF).
Bristol Myers Squibb's (BMS) Sotyktu (deucravacitinib) has been authorised for use in Great Britain to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
Bristol Myers Squibb (BMS) and Tubulis have announced an agreement aimed at developing differentiated antibody-drug conjugates (ADCs) for solid tumours.
Bristol Myers Squibb's (BMS') plaque psoriasis treatment, Sotyktu (deucravacitinib), has been approved by the European Commission (EC) for adults with moderate-to-severe cases who are candidates for systemic therapy.
No results were found
Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...